Profitability Ratios
| Ratio |
Value |
| GP Margin |
88.5% |
| EBIT Margin |
-891.6% |
| EBITDA Margin |
-880.6% |
| Operating Margin |
-695.4% |
| Pretax Margin |
-891.6% |
| Cont. Ops Margin |
-891.6% |
| Net Margin |
-891.6% |
| Bottom Line Margin |
-891.6% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
4.53 |
| Quick Ratio |
4.53 |
| Solvency Ratio |
-0.372 |
| Cash Ratio |
4.36 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.40 |
| Forward PEG |
-0.40 |
| Price/Book |
-11.56 |
| Price/Sales |
86.62 |
| Price/FCF |
-14.26 |
| Price/Op Cash Flow |
-14.95 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.9015 |
| Debt/Equity |
-1.9469 |
| Debt/Capital |
2.0560 |
| Long-Term Debt/Capital |
2.4454 |
| Financial Leverage |
-2.16 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.11 |
| Operating Cash Flow Ratio |
-2.519 |
| Operating Cash Flow/Sales |
-579.3% |
| Free Cash Flow/Operating Cash Flow |
104.9% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-5.34 |
| Interest Coverage |
-5.8946 |
| Short-Term Operating Cash Flow Coverage |
-12.38 |
| Operating Cash Flow Coverage |
-0.40 |
| Capital Expenditure Coverage |
-20.56 |
| Dividend + Capital Expenditure Coverage |
-20.56 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.73 |
| EPS |
-6.540 |
| Debt/Share |
11.5653 |
| Cash/Share |
7.35 |
| Book Value/Share |
-5.50 |
| Tangible BV/Share |
-5.50 |
| Equity/Share |
-5.50 |
| Operating Cash Flow/Share |
-4.249 |
| Capital Expenditure/Share |
0.207 |
| FCF/Share |
-4.456 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.000 |
| Earnings Before Tax/EBIT |
1.282 |
| Price/Fair Value |
-11.56 |
| Debt/Market Cap |
0.1517 |
| Effective Tax Rate |
0.0% |
| Enterprise Value Multiple |
-10.36 |
CYTK - Cytokinetics, Incorporated